Chiriboga Reyes Gustavo, Pallares Vela Elisa, Bernad Peter G
Neurology, Neurology Services, Inc, Washington, USA.
Neurology, George Washington University Hospital, Washington, USA.
Cureus. 2023 Sep 25;15(9):e45959. doi: 10.7759/cureus.45959. eCollection 2023 Sep.
Hashimoto's encephalopathy (HE) is a rare diagnosis. Establishing the diagnosis itself is quite challenging, as symptoms vary among cases and there is still no standard confirmatory test. The clinical presentation is heterogeneous; however, patients with HE most commonly experience focal neurological deficits, frequently accompanied by cognitive dysfunction, aphasia, or paresis. The most widely recommended initial treatment for cases of HE is a course of corticosteroids. Nonetheless, their response varies from patient to patient, and some may become resistant to them. There are many proposed second-line treatments; however, there is little data and no consensus on the best alternative treatment when steroid therapy fails. This article provides an update on a case of cerebellar ataxia in a 30-year-old female patient with Hashimoto's thyroiditis. She initially presented with rapid-onset progressive symptoms of cerebellar ataxia (movement incoordination, dysmetria, and balance problems) and had elevated serum anti-thyroid peroxidase antibodies. She was diagnosed with HE and was initially treated with methylprednisolone. However, her symptoms recurred after tapering steroid therapy, and eventually, they ceased to manage her symptoms, plus she developed steroid-induced osteoporosis. She began treatment with intravenous immunoglobulin (IVIG) as an alternative in April 2022. Since then, she has had four infusions of IVIG that have allowed her to remain symptom-free.
桥本脑病(HE)是一种罕见的诊断。确立该诊断本身颇具挑战性,因为不同病例症状各异,且尚无标准的确诊检查。临床表现具有异质性;然而,HE患者最常出现局灶性神经功能缺损,常伴有认知功能障碍、失语或轻瘫。对于HE病例,最广泛推荐的初始治疗是一个疗程的皮质类固醇。尽管如此,患者对其反应因人而异,有些患者可能会产生耐药性。有许多二线治疗方案被提出;然而,当类固醇治疗失败时,关于最佳替代治疗的数据很少且没有共识。本文介绍了一名30岁患有桥本甲状腺炎的女性患者小脑共济失调病例的最新情况。她最初表现为小脑共济失调的快速进展症状(运动不协调、辨距不良和平衡问题),血清抗甲状腺过氧化物酶抗体升高。她被诊断为HE,最初接受甲泼尼龙治疗。然而,在逐渐减少类固醇治疗后症状复发,最终,这些症状无法控制,此外她还出现了类固醇诱导的骨质疏松症。2022年4月,她开始接受静脉注射免疫球蛋白(IVIG)作为替代治疗。从那时起,她接受了四次IVIG输注,使她一直没有症状。